Key PointsWith 49 years of consecutive dividend increases under its belt, Medtronic is one year away from becoming a Dividend King.

How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?

Key PointsBoeing's board now has more directors with deep aviation experience.

Boeing's Secret Weapon Isn't on the Factory Floor -- It's in the Boardroom

Key PointsMedtronic struggled with macro, operational, and forex headwinds in recent years.

Medtronic Is Just 1 Year From Dividend King Status. Should You Buy the Stock Before It Gets There?

(RTTNews) - Medtronic plc (MDT), a global healthcare technology company, announced a final exchange ratio of 4.5939 MiniMed Group (MMED) shares for each Medtronic ordinary share accepted in its previously announced exchange offer.

Medtronic Finalizes 4.5939 Exchange Ratio As MiniMed Split-Off Nears Completion 

Fintel reports that on October 7, 2026, Barclays initiated coverage of Medtronic (NYSE:MDT) (WBAG:MDT) with a Equal-Weight recommendation.Medtronic plc is a globally recognized medical device company based in Dublin, Ireland. The company primarily operates in the healthcare secto

Barclays Initiates Coverage of Medtronic at Equal-Weight

Key PointsThe conflict in the Middle East is driving up energy prices, which impacts costs throughout the economy.

The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Medtronic plc News